Press Releases
Apr 23, 2024
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU)...

Apr 22, 2024
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), and...

Apr 3, 2024
U.S. FDA Accepts Astellas’ Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

- sNDA seeks to include positive 2-year data for IZERVAY - - Target action date set for November 19, 2024 - TOKYO, April 1, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki...

EXPLORE ALL US PRESS RELEASES

Articles
Feb 8, 2024
From Recurrence to Perseverance: Jim's Prostate Cancer Story

As a civilian partner working for the Army for many years following his time in Vietnam, Jim didn’t suspect anything was amiss when he went for his annual health exam in 2006. However, during...

Dec 15, 2023
Astellas Recognized for its Support of the LGBTQ+ Community through Human Rights Campaign Foundation’s Annual Corporate Equality Index

Astellas is proud to be featured on the Human Rights Campaign Foundation’s (HRC) annual Corporate Equality Index (CEI) for its continued support of the LGBTQ+ community within the workplace....

Oct 10, 2023
Astellas Recognized as a Top Company for Working Parents

Astellas ranked in Seramount’s 2023 “100 Best Companies” list for the ninth consecutive year This year, Astellas once again was named as a top company for working parents on Seramount’s...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Download Fact Sheet

Download Fact Sheet

Sustainability

Sustainability

Investors

Investors

Explore U.S. Products

Explore U.S. Products